| Literature DB >> 20932759 |
Italo Beria1, Barbara Valsasina, Maria Gabriella Brasca, Walter Ceccarelli, Maristella Colombo, Sabrina Cribioli, Gabriele Fachin, Ronald D Ferguson, Francesco Fiorentini, Laura M Gianellini, Maria L Giorgini, Jurgen K Moll, Helena Posteri, Daniele Pezzetta, Fulvia Roletto, Francesco Sola, Dania Tesei, Michele Caruso.
Abstract
A series of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives was optimized as Polo-like kinase 1 inhibitors. Extensive SAR afforded a highly potent and selective PLK1 compound. The compound showed good antiproliferative activity when tested in a panel of tumor cell lines with PLK1 related mechanism of action and with good in vivo antitumor efficacy in two xenograft models after i.v. administration.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20932759 DOI: 10.1016/j.bmcl.2010.09.060
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823